Pharvaris (PHVS) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pharvaris, a Dutch biopharmaceutical company, has executed the second amendment to its License Agreement with Germany’s BRAIN Biotech AG, effective September 20, 2024. The amendment facilitates the sale of BRAIN Biotech’s revenue rights from Pharvaris to Royalty Pharma and clarifies terms regarding the duration of Pharvaris’s payment obligations. This adjustment reflects an ongoing commitment to managing their intellectual property and financial strategy in the pharmaceutical industry.
For further insights into PHVS stock, check out TipRanks’ Stock Analysis page.